Lung Cancer Trial, Recruiting (NCT07096258)

Lung Cancer Trial, Recruiting NCT07096258 Sponsor: Hedera Dx SA Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT07096258 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People diagnosed with non-small cell lung cancer (a type of lung cancer) that has spread locally or to other parts of the body and cannot be surgically removed (stages IIIB, IIIC, or IV).
People who have not yet received any treatment for this advanced stage of their lung cancer.
People who are planning to start a first course of treatment for this advanced lung cancer.
People whose general health and ability to carry out daily activities meets a certain minimum level, known as an ECOG score of 2 or below — meaning they are able to care for themselves, even if they are unable to do all physical activity (confirm with trial site).
People who are at least 18 years old at the time of signing the consent form and are able to give their own informed consent.

Who may not be able to join:

People who have had another type of cancer (other than the lung cancer being studied, or an early-stage, non-invasive cervical cancer) at any point in the five years before enrolling in the trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Dr. Christian Meisel, MD PhD, Hedera Dx

Phone: +41 21 588 16 54

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07096258

Sponsor: Hedera Dx SA

Phase: Not Applicable

Status: Recruiting

Condition: Lung Cancer

Trial contact: +41 21 588 16 54

More information: https://clinicaltrials.gov/study/NCT07096258

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People diagnosed with non-small cell lung cancer (a type of lung cancer) that has spread locally or to other parts of the body and cannot be surgically removed (stages IIIB, IIIC, or IV).
People who have not yet received any treatment for this advanced stage of their lung cancer.
People who are planning to start a first course of treatment for this advanced lung cancer.
People whose general health and ability to carry out daily activities meets a certain minimum level, known as an ECOG score of 2 or below — meaning they are able to care for themselves, even if they are unable to do all physical activity (confirm with trial site).
People who are at least 18 years old at the time of signing the consent form and are able to give their own informed consent.

Who may not be able to join:

People who have had another type of cancer (other than the lung cancer being studied, or an early-stage, non-invasive cervical cancer) at any point in the five years before enrolling in the trial.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Hedera Dx SA

Registry

ClinicalTrials.gov

Start date

1 June 2024

Est. completion

1 December 2027

Where this trial is recruiting

🇫🇷 France 🇮🇹 Italy 🇪🇸 Spain 🇨🇭 Switzerland

Primary endpoints

Actionable biomarkers

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov